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Abstract
We report 2 cases of small cell carcinoma (SmCC) of the stomach with distant metastasis that
were treated with the same chemotherapeutic regimens as used to treat small cell lung cancer. Al-
though the mean survival of patients with SmCC of the stomach is reported to be only 7 months,
our patients survived for 15 and 14 months, respectively. In our experience, these chemothera-
peutic regimens might provide a survival benefit for patients with SmCC of the stomach, although
they demonstrated no remarkable antitumor effects.
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We report 2 cases of small cell carcinoma (SmCC) of the stomach with distant metastasis that were 
treated with the same chemotherapeutic regimens as used to treat small cell lung cancer.  Although the 
mean survival of patients with SmCC of the stomach is reported to be only 7 months,  our patients 
survived for 15 and 14 months,  respectively.  In our experience,  these chemotherapeutic regimens 
might provide a survival beneﬁt for patients with SmCC of the stomach,  although they demonstrated 
no remarkable antitumor eﬀects.
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rimary small cell carcinoma (SmCC) of the 
stomach,  synonymous with neuroendocrine 
carcinoma of the stomach,  is a rare neoplasm that 
represents less than 0.1ｵ of all primary gastric can-
cers [1-4].  This neoplasm is one of the most aggres-
sive cancers,  and has a very poor prognosis [5].  In 
fact,  the mean survival of patients with primary 
SmCC of the stomach is reported to be 7 months [6].
　 The choice of treatment for this disease remains 
controversial.  The therapeutic value of surgery,  sys-
temic chemotherapy,  and locoregional chemotherapy 
is often limited.  Some authors have suggested that the 
chemotherapy regimens for small cell lung cancer 
(SCLC) may be suitable for patients with this disease 
due to the similarity in biological and clinical charac-
teristics between SmCC of the stomach and SCLC 
[5,  7,  8].  We report herein 2 cases with advanced 
primary SmCC of the stomach who were treated with 
the same chemotherapy regimens as used to treat 
SCLC.  The resulting survival times for these 2 
patients were over 15 and 14 months,  respectively.
Case Report
　 Case 1. A 79-year-old Japanese woman had 
been undergoing treatment for liver cirrhosis due to 
hepatitis C virus infection for several years.  A peri-
odic computed tomography (CT) scan incidentally 
revealed an enlarged lymph node around the lesser 
curvature of the stomach and a hypoattenuated lesion 
in the spleen (Fig.  1).  The patient was asymptomatic,  
and her physical examinations were unremarkable.  
Laboratory studies revealed a low white blood cell 
count of 2,900/mm3 and a low platelet count of 
53,000/mm3,  due to the hypersplenism.  Liver func-
tion tests showed a normal bilirubin level,  and slightly 
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elevated transaminase levels.  Tumor markers includ-
ing carcinoembryonic antigen (CEA),  carbohydrate 
antigen 19-9,  alphafetoprotein,  des-gamma-carboxy 
prothrombin,  neuron-speciﬁc enolase (NSE),  and pro-
gastrin-releasing peptide were all within normal limits.
　 Esophagogastroduodenoscopy (EGD) disclosed a 
gastric cancer of Borrman type 2 with a diameter of 
25mm (Fig.  2).  Pathologic examination of the biopsy 
specimens revealed small or medium-sized cancer cells 
with irregular nuclei and scant cytoplasm (Fig.  3).  
The tumor cells were weakly positive for immunohis-
tochemical staining with chromogranin.  Based on the 
histological ﬁndings,  the diagnosis of SmCC was con-
ﬁrmed.  No adenocarcinoma component was detected in 
the biopsy specimens.  Neither the swollen lymph node 
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Fig. 1　 Contrast-enhanced computed tomography scan of case 1.  
An enlarged lymph node 20mm in diameter was demonstrated 
around the lesser curvature of the stomach (white arrow).  A hypoat-
tenuated lesion 10mm in diameter was also revealed in the spleen,  
which was considered to be a metastasis of small cell carcinoma of 
the stomach (black arrow).
Fig. 2　 Esophagogastroduodenoscopic image from case 1.  A 
tumor of Borrman type 2 in the lesser curvature of the gastric body 
can be observed.
A B
Fig. 3　 Histological appearance of the small cell carcinoma of the stomach in case 1.  Biopsy specimens revealed small or medium-
sized cancer cells with irregular nuclei and scant cytoplasm (A); hematoxylin and eosin staining.  The tumor cells were weakly positive for 
chromogranin (B); immunohistochemical staining with chromogranin.  Scale bars＝200µm.
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around the stomach nor the hypoattenuated lesion in 
the spleen had been detected by CT over the previous 
year,  so both ﬁndings were considered to be metasta-
ses of SmCC.  Contrast-enhanced CT of the whole 
body revealed no tumor in the lung or other organs.  
The clinical diagnosis based on these ﬁndings was 
primary SmCC of the stomach,  Ｔ2 Ｎ1 Ｈ0 Ｐ0 CYx 
Ｍ1: c Stage IV,  according to the Japanese Classiﬁ-
cation of Gastric Carcinoma (9).
　 The doses of the chemotherapeutic agents were 
reduced due to the low platelet count.  The ﬁrst line 
of chemotherapy consisted of i.v.  carboplatin (AUC
＝4) on Day 1,  plus i.v.  etoposide at a dose of 
50mg/m2 daily for 3 days on Days 1-3,  every 4 
weeks (Fig.  4).  The patientʼs condition remained sta-
ble during four cycles of the chemotherapy,  but after 
5 cycles,  paraaortic lymphadenopathy newly appeared,  
while the size of the primary gastric tumor had not 
changed.  The second line of chemotherapy consisted 
of i.v.  nogitecan hydrochloride at a dose of 0.8mg/m2 
daily for 5 days on Days 1-5,  every 3 weeks.  Both the 
primary gastric lesion and lymphadenopathy were 
enlarged after 2 cycles of the chemotherapy,  so the 
presence of progressive disease was acknowledged.  
The third line of chemotherapy was i.v.  amrubicin 
hydrochloride 35mg/m2 daily for 3 days on Days 1-3,  
but this regimen was stopped after one cycle due to the 
hematologic toxicity.  The fourth line of chemotherapy 
consisted of i.v.  paclitaxel at a dose of 45mg/m2 daily 
for 2 days on Days 1 and 8,  every 3 or 4 weeks.  
After 3 cycles of the chemotherapy,  disease progres-
sion was still observed.  The ﬁfth line of chemother-
apy was i.v.  gemcitabine hydrochloride at a dose of 
500mg/m2 for 2 days on Days 1 and 8.  A new meta-
static lesion appeared on the skin of the patientʼs right 
forearm during the course of therapy.  Her condition 
continued to worsen and died 15 months after the 
diagnosis of SmCC of the stomach.
　 Case 2. A 78-year-old Japanese male presented 
with a backache in the middle of his back that had 
begun 2 weeks earlier.  The patient had neither a 
relevant history nor a contributory family history.  His 
physical examinations were unremarkable.  Labora-
tory studies revealed a normal complete blood count 
and normal levels of liver enzymes.  NSE was elevated 
to 23.66ng/ml (normal 0-15.2).  The other tumor 
markers were all within the normal limits.  An ultra-
sound examination revealed 3 tumors in the liver,  and 
these liver tumors were identiﬁed as low-density 
masses in a contrast-enhanced CT scan.  There was no 
tumor in the lungs or lymphadenopathy on CT scans.  
EGD disclosed a gastric cancer of Borrman type 2 
with a diameter of 35mm in the posterior wall of the 
gastric body (Fig.  5).  Pathological examination of the 
biopsy specimen conﬁrmed the diagnosis of SmCC 
(Fig.  6).  A bone scintigraphy exam showed multiple 
metastatic lesions in the thoracic spine,  the right 
sacrum,  and the right ischium.  The clinical diagnosis 
based on these ﬁndings was primary SmCC of the 
stomach with metastases to the bone and the liver,  Ｔ2 
Ｎ0 Ｈ1 Ｐ0 CYx Ｍ1: c Stage IV.
　 Opioids and non-steroidal anti-inﬂammatory drugs 
were administered for the patientʼs backache due to the 
bone metastasis,  and a total of 40 Gy of radiotherapy 
was administered to the thoracic spine (Fig.  7).  The 
backache was temporarily alleviated by the radio-
therapy and the analgesics.  The ﬁrst line of chemo-
therapy consisted of i.v.  carboplatin (AUC＝5) on 
Day 1,  plus i.v.  etoposide at a dose of 70mg/m2 daily 
for 3 days on Days 1-3,  every 4 weeks.  Both the 
primary gastric lesion and the hepatic tumors were 
enlarged after two cycles of the chemotherapy.  The 
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CEA 1.7 1.5 1.2 1.5 1.0 1.4 3.2 (ng/ml)
NSE 6.4 8.4 19.7 16.8 22.0 75.6 96.1 (ng/ml)
CBDCA+VP16
5 cycles
Topotecan
2 cycles
Amru-
bicin
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3 cycles
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Fig. 4　 Clinical course of case 1.  CBDCA,  carboplatin; VP16,  etoposide; PTX,  paclitaxel; GEM,  gemcitabine hydrochloride; CEA,  
carcinoembryonic antigen; NSE,  neuron-speciﬁc enolase.
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second and third lines of chemotherapy consisted of 
0.8mg/m2 nogitecan hydrochloride and 35mg/m2 
amrubicin hydrochloride,  respectively.  However,  no 
remarkable responses were achieved with those regi-
mens.  Thereafter,  the patient rapidly deteriorated 
and died 15 months after the diagnosis.
Discussion
　 The vast majority of SmCC develop in the lung,  
with only 2.5ｵ of SmCC present at extrapulmonary 
sites [10,  11],  including the stomach,  esophagus,  
colon,  pancreas,  minor salivary organs,  pharynx,  and 
uterine cervix.  The morphological features of extra-
pulmonary SmCC are identical to those of SCLC 
[12].
　 To the best of our knowledge,  213 cases of pri-
mary SmCC of the stomach have been reported in the 
literature (168 males,  44 females,  1 unspeciﬁed).  
The patients ranged in age from 28 to 89 years,  with 
a mean of 65.1 years,  at initial diagnosis.  The gross 
type was type 0-I in 2,  0-IIa in 2,  0-IIa＋IIc in 3,  
0-IIb in 1,  0-IIb＋Ia in 1,  0-IIc in 3,  0-IIc＋IIa in 
4,  0-III＋IIc in 1,  type 1 in 30,  type 2 in 67,  type 3 
in 46,  type 4 in 3,  and type 5 in 8 cases (unspeciﬁed 
in 42 cases),  according to the Japanese Classiﬁcation 
of Gastric Carcinoma (9).  The tumor sizes ranged in 
diameter from 8 to 185mm,  with a mean of 58.7mm.  
The tumor was limited to the mucosa or submucosa in 
only 15 cases,  whereas 112 cases presented with 
advanced-stage disease.  The overall median survival 
time (MST) was only 9 months (range: 0-96 months).  
In general,  the clinical behavior of primary SmCC of 
the stomach is generally aggressive,  similar to that of 
SCLC [13].  Nodal involvement and distant metasta-
ses are frequently observed at the initial presentation 
[14,  15].  Because of its clinicopathological aggres-
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Fig. 5　 Esophagogastroduodenoscopic image in case 2.  A can-
cer of Borrman type 2 in the posterior wall of the gastric body was 
revealed.
A B
Fig. 6　 Histological appearance of the small cell carcinoma of the stomach in case 2.  Cancer cells with irregular nuclei and scant 
cytoplasm were arranged in a trabecular pattern (A); hematoxylin and eosin staining.  The cancer cells were positive for synaptophysin 
(B); immunohistochemical staining with synaptophysin.  Scale bars: 200µm.
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siveness,  this disease is considered to have a poor 
prognosis [6].  Although a standard treatment has not 
yet been established for primary SmCC of the stom-
ach,  surgery may play an important role in cases 
without distant metastasis.  Of the cases reported in 
the literature,  surgery without adjuvant chemother-
apy was performed in 77 cases and the MST was 20 
months.  Alternatively,  47 patients underwent various 
regimens of chemotherapy as adjuvant therapy after 
surgery.  Among these,  15 received etoposide-based 
or irinotecan-based chemotherapy and the MST was 
15 months.  5-ﬂuorouracyl (5-FU)-based chemotherapy 
was applied for 21 patients,  uracyl/tegafur (UFT)-
based chemotherapy for 11,  and tegafur/gimeracil/
oteracil potassium (S-1)-based chemotherapy for 16,  
and the MST was 17,  12,  and over 20 months,  
respectively.
　 In contrast,  17 cases of primary SmCC of the 
stomach treated by monotherapy with cytotoxic agents 
have been reported.  Although various regimens of 
chemotherapy were administered to these patients,  
only 3 of the 17 cases survived over 12 months after 
the initial diagnosis [16-18].  Carboplatin and etopo-
side were administered in one patient who survived for 
only 7 months [19],  and cisplatin and etoposide were 
administered in 2 patients who survived for 9 and 11 
months,  respectively [20,  21].  None of these 3 cases 
underwent salvage regimens.  Both of the present 
patients survived over 12 months with carboplatin and 
etoposide together with salvage regimens that are 
usually applied to patients with SCLC.  Thus,  these 
chemotherapeutic regimens might improve the progno-
sis of patients with SmCC of the stomach with distant 
metastasis.
　 Among elderly Japanese patients with SCLC,  
chemotherapy with carboplatin and etoposide has 
achieved a response rate of 75ｵ and a median sur-
vival time of 10.8 months,  with less toxicity than 
treatment by cisplatin and etoposide [22].  This regi-
men seems to have similar eﬀects on primary SmCC 
of the stomach,  possibly because of the biological 
resemblance between SmCC and SCLC [23].  Single-
agent topotecan is one of the most frequently used 
drugs in the second-line regimen for patients with 
SCLC.  Topotecan has yielded response rates of 
approximately 20ｵ,  with median survival times of 
approximately 6.3 months [24].  Amrubicin [25],  
paclitaxel [26],  and gemcitabine [27] have also 
exhibited signiﬁcant activity against relapsed SCLC.  
We therefore administered carboplatin and etoposide,  
single-agent topotecan,  amrubicin,  paclitaxel,  and 
gemcitabine hydrochloride as the ﬁrst-,  second-,  
third-,  fourth-,  and ﬁfth-line regimens for the present 
patients,  respectively.  However,  although the present 
patients with distant metastases survived for 15 and 
14 months,  no remarkable response against the tumor 
was achieved.  It should be investigated in the future 
whether chemotherapy regimens showing some success 
against SCLC can prevent the tumor progression of 
SmCC of the stomach and thus provide a survival 
beneﬁt for these patients.
　 On the other hand,  S-1,  which contains a prodrug 
of 5-FU,  has been widely used as the main drug to 
treat gastric adenocarcinomas in Japan.  In a previous 
report of a case of primary SmCC of the stomach 
treated by chemotherapy with S-1 and cisplatin,  the 
patient survived for 14 months [16].  In addition,  as 
described above,  S-1 has been shown to have a supe-
rior eﬀect as an adjuvant chemotherapeutic drug for 
gastric SmCC compared with other agents.  Thus S-1 
is another candidate key drug that could possibly 
improve the prognosis of patients with SmCC of the 
stomach [14].
　 In conclusion,  our 2 patients with SmCC of the 
stomach underwent chemotherapeutic regimens with 
carboplatin and etoposide,  and the salvage regimens 
that are usually applied to SCLC.  With this treat-
ment,  they survived for 15 and 14 months despite 
distant metastases.  However,  the treatment regimens 
appeared to have no signiﬁcant antitumor eﬀects.  
Comparative analysis between these regimens and S-1-
based regimens should be performed in the future.
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Fig. 7　 Clinical course of case 2.
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